{
    "organizations": [],
    "uuid": "81c28e75e0266f42fecabe9716baf7965d0c1b8c",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/19/pr-newswire-gbt-reports-fourth-quarter-2017-results.html",
    "ord_in_thread": 0,
    "title": "GBT Reports Fourth Quarter 2017 Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "MONTEVIDEO, Uruguay, March 19, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q17 and full year of 2017.\nHIGHLIGHTS\nGross revenues for 4Q17 grew 14% in constant currency, totaling BRL 271.6M.\nNet revenues for 4Q17 increased by 17.8% in constant currency, totaling BRL 244.4M.\nGross profit up 14.4% in 4Q17, in constant currency, totaling BRL 140.3M. Gross margin of 57.4%.\nAdjusted EBITDA grew 5.5% in constant currency vs. 4Q16, amounting to BRL 73.2M in 4Q17. 19.2% growth excluding from the base an insurance recovery decoupled from its underlying loss (in 2Q17)\nAdjusted net income up 6.9% in nominal terms from 4Q16, reaching BRL 36.9M in 4Q17.\nNet revenues for full year 2017 at 817.5M, with 14% organic growth (excluding exchange rate effects, short-term businesses, divestitures and acquisitions).\nAdjusted EBITDA reached BRL 199.4M in 2017, up 23.9% in constant currency.\nGross margin for full year 2017 improved 3.8 pp when compared to 2016, reaching 53.8%. Adjusted EBITDA margin improved 2.5 pp, reaching 24.4%, in the same period.\nContacts:\nMelissa Angelini\nir@grupobiotoscana.com\n+55 11 5090-5927\nView original content: http://www.prnewswire.com/news-releases/gbt-reports-fourth-quarter-2017-results-300616306.html\nSOURCE Grupo Biotoscana",
    "published": "2018-03-20T02:46:00.000+02:00",
    "crawled": "2018-03-20T05:06:39.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "montevideo",
        "uruguay",
        "march",
        "biotoscana",
        "investment",
        "b3",
        "gbio33",
        "biopharmaceutical",
        "group",
        "operates",
        "latin",
        "america",
        "announced",
        "today",
        "result",
        "4q17",
        "full",
        "year",
        "highlight",
        "gross",
        "revenue",
        "4q17",
        "grew",
        "constant",
        "currency",
        "totaling",
        "brl",
        "net",
        "revenue",
        "4q17",
        "increased",
        "constant",
        "currency",
        "totaling",
        "brl",
        "gross",
        "profit",
        "4q17",
        "constant",
        "currency",
        "totaling",
        "brl",
        "gross",
        "margin",
        "adjusted",
        "ebitda",
        "grew",
        "constant",
        "currency",
        "4q16",
        "amounting",
        "brl",
        "4q17",
        "growth",
        "excluding",
        "base",
        "insurance",
        "recovery",
        "decoupled",
        "underlying",
        "loss",
        "2q17",
        "adjusted",
        "net",
        "income",
        "nominal",
        "term",
        "4q16",
        "reaching",
        "brl",
        "4q17",
        "net",
        "revenue",
        "full",
        "year",
        "organic",
        "growth",
        "excluding",
        "exchange",
        "rate",
        "effect",
        "business",
        "divestiture",
        "acquisition",
        "adjusted",
        "ebitda",
        "reached",
        "brl",
        "constant",
        "currency",
        "gross",
        "margin",
        "full",
        "year",
        "improved",
        "pp",
        "compared",
        "reaching",
        "adjusted",
        "ebitda",
        "margin",
        "improved",
        "pp",
        "reaching",
        "period",
        "contact",
        "melissa",
        "angelini",
        "ir",
        "view",
        "original",
        "content",
        "http",
        "source",
        "grupo",
        "biotoscana"
    ]
}